Huadong Medicine News

East China Pharmaceutical (000963) Annual Report Review: Improving the layout of regeneration+HA+ botulism pipelines, the ability to contribute to the profitability of the medical and aesthetic business is expected to continue to improve

信達證券Apr 18 18:41

Depth* Company* East China Pharmaceutical (000963): Medicine and Aesthetics Maintain Rapid Growth, Pharmaceutical Industry Innovation Achievements Gradually Realize

中銀證券Apr 18 18:21

Bank of China Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) maintaining steady growth in performance and maintaining investment in

Zhitong FinanceApr 18 16:37

Huadong Pharmaceutical (000963): Profit growth accelerated in 4Q23

華泰證券Apr 18 09:51

East China Pharmaceutical (000963): The pharmaceutical industry has accumulated and developed innovative pipelines and entered the harvest period

天風證券Mar 29 15:56

East China Pharmaceutical (000963) 23-year performance forecast review: Medical and aesthetic business continues to grow, and we expect the ability to contribute to profits will continue to increase

信達證券Feb 2 07:41

East China Pharmaceutical (000963): Steady growth of the four major businesses, intensive catalytic drive continuous growth through innovative products

方正證券Feb 2 07:21

East China Pharmaceutical (000963): Steady growth in performance and the innovation pipeline is expected to gradually be realized

國泰君安Feb 1 20:31

Huadong Pharmaceutical (000963): Steady growth in overall performance, optimistic that it will continue to be delivered in the research pipeline

國金證券Jan 31 00:00

East China Pharmaceutical (000963) 2023 Third Quarter Report Commentary: Profit Levels Increase, Profits Exceed Expectations

華創證券Nov 16, 2023 19:57

Huadong Pharmaceutical (000963): Signed an equity investment & exclusive product distribution agreement with Chongqing Yuyan to restructure Botulics to further improve the company's botulism pipeline layout

信達證券Nov 15, 2023 19:52

Huadong Pharmaceutical (000963): Strategy to Reshape Beauty and Revitalize

上海證券Nov 15, 2023 18:17

Huaxin Securities: Optimistic about GLP-1RA's flexible growth in the field of multiple chronic diseases and the industry's “recommended” rating

Zhitong FinanceNov 14, 2023 14:06

East China Pharmaceutical (000963) 2023 three-quarter report review: Pharmaceuticals maintain steady growth, increase in the profit contribution rate of the medical and aesthetic business

長江證券Oct 31, 2023 00:00

Deep* Company* Huadong Pharmaceutical (000963): Overall performance maintained steady growth, and medical and aesthetic business grew strongly

中銀證券Oct 27, 2023 07:42

HUADONG MEDICINE(000963):PERFORMANCE IN LINE WITH EXPECTATIONS; BUSINESS PRESENCE IN ALL SEGMENTS EXTENDED

兴业证券Oct 27, 2023 00:00

Huadong Pharmaceutical (000963): Steady growth in the industrial sector, improvement in profitability in the medical and aesthetic sector

國泰君安國際Oct 26, 2023 19:02

Huadong Pharmaceutical (000963): Performance is in line with expectations, and the layout of various sectors has been further deepened

興業證券Oct 26, 2023 09:42

East China Pharmaceutical (000963) 2023 Third Quarter Report Review: Steady Growth in the Industrial Sector, Improvement in Profits in the Medical and Aesthetic Sector

國泰君安Oct 26, 2023 00:00

Huadong Pharmaceutical (000963): Medical and aesthetic development is rapid and GLP-1 in-depth layout, and the company's performance continues to grow steadily

安信證券Oct 25, 2023 18:46